Valeant Pharmaceuticals International Inc $116.21

down -0.89


27/8/2014 03:14 PM  |  NYSE : VRX  
Industries : Drugs / Drug Delivery & Accessories
Get Trend Analysis Icon Get VRX Trend Analysis - it has underperformed the S&P 500 by 9%

Partner Headlines

  1. Gilead, Jazz Among 4 Top Big Cap Medicals To Watch

    IBD
  2. IBD's Special 8-Week Hold Rule Has Faced Tough 2014

    IBD
  3. SALIX PHARMACEUTICALS

    IBD
  4. Benzinga's M&A Chatter for Tuesday August 19, 2014

    Benzinga
  5. Salix Soars On Allergan Buzz

    IBD
  6. Indexes Rally On Strong Housing Data, Retail Reports

    IBD
  7. Allergan Reportedly Eyes Salix To Avoid Valeant Deal

    IBD
  8. Allergan Takes In 13 New Hedge Fund Investments In Q2

    Benzinga
  9. Markets Gather Some Momentum As Volume Remains Light, Geopolitical Tension ...

    Benzinga
  10. Benzinga's M&A Chatter for Monday August 11, 2014

    Benzinga
  11. Valeant Pharmaceuticals'

    IBD
  12. Valeant Pharmaceuticals Part X: a follow up on the sale of facial injectables

    GuruFocus
  13. Allergan Rebounds After Analyst Upgrades On Valuation

    IBD
  14. Prescription Drugmakers Slide Down Industry Rankings

    IBD
  15. Salix, Actavis Lead IBD 50 Drug Earnings This Week

    IBD
  16. Thursday's Selling Momentum Continues In To Friday

    Benzinga
  17. Thursday's Selling Momentum Continues Into Friday

    Benzinga
  18. Valeant, Ackman's Pershing Square Issue Response to 'Frivolous Allergan ...

    Benzinga
  19. Valeant Guides Outlook Low

    IBD
  20. Dow Suffers 300 Point Drop; S&P 500 And Nasdaq Also Tumble

    Benzinga
  21. Valeant Q2 Meets Views; Guidance Down On Asset Sale

    IBD
  22. UPDATE: Valeant Pharmaceuticals Posts Higher Q2 Profit

    Benzinga
  23. Stocks End Mixed; Akamai Falls, Yelp Rises After Hours

    IBD
  24. Diamond Hill Capital Comments on Valeant Pharmaceuticals International ...

    GuruFocus
  25. BTIG: Valeant Must Sweeten Allergan Bid To More Than $200/Share

    Benzinga
  26. Allergan EPS Gains Accelerate

    IBD
  27. Allergan Earnings Growth, Job Cuts Counter Valeant

    IBD
  28. UPDATE: Valeant Complains to SEC Regarding Allergan Claims

    Benzinga
  29. Valeant Submits HSR Filing Related to Proposed Allergan Deal

    Benzinga
  30. Benzinga's M&A Chatter for Wednesday July 9, 2014

    Benzinga
  31. Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking ...

    Benzinga
  32. Chipotle, Keurig Near Buy Points; Energy Dominates

    IBD
  33. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  34. Benzinga's M&A Chatter for Wednesday June 25, 2014

    Benzinga
  35. Paulson builds Allergan stake

    IBD
  36. Rumor: Big Stake In Allergan Acquired By Valeant Supporter Paulson

    Benzinga
  37. Markets Close Higher Despite A Contraction In GDP

    Benzinga
  38. Benzinga's M&A Chatter for Tuesday June 24, 2014

    Benzinga
  39. Indexes Mixed As Stocks Pare Earlier Gains

    IBD
  40. Walgreen Falls On Weak Earnings, Alliance Boots Reset

    IBD
  41. 'Merger Monday' Deals, Offers And Rejections

    Benzinga
  42. Allergan Rebuffs Valeant's Tender Offer

    FoxBusiness
  43. Akorn

    IBD
  44. Akorn Shares Gaining On $41 Million Sale Of Branded Drugs Unit To Valeant

    Benzinga
  45. Shire Rejects AbbVie's $46 Bil Tax-Inversion Attempt

    IBD
  46. Valeant launches hostile bid

    IBD
  47. M&A Activity Helps Fuel Healthy Action In Drugmakers

    IBD
  48. Benzinga's M&A Chatter for Wednesday June 18, 2014

    Benzinga
  49. 5-Star Biotech Stock Watch: Synta Pharmaceuticals

    Benzinga
  50. Stocks Meander As Fed Announcement Looms

    IBD
Trading Center